Publicacións en colaboración con investigadores/as de Eli Lilly and Company (2)

2019

  1. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

    The Lancet, Vol. 394, Núm. 10193, pp. 121-130

  2. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

    The Lancet, Vol. 394, Núm. 10193, pp. 131-138